Highlights Vor Biopharma Inc.

Equities

VOR

US9290331084

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-11 pm EDT			5-day change	1st Jan Change
1.25 ^USD	-3.85%		-5.30%	-44.44%

Jun. 10	Vor Biopharma Inc. Announces Management Appointments, Effective June 21, 2024	CI
Jun. 10	Nathan Jorgensen Resigns as Chief Financial Officer of Vor Biopharma Inc., Effective June 21, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vor Biopharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Vor Biopharma Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 20	CI
Vor Biopharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Vor Bio Doses First AML Patient with VCAR33	Jan. 17	CI
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference	Nov. 09	CI
Vor Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Vor Bio Announces Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform	Nov. 02	CI
Vor Biopharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Vor Biopharma Inc. Presents Updated Clinical Data from Patients Treated in VBP101	23-06-09	CI
Vor Biopharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
VOR BIOPHARMA INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-03-23	AQ
Vor Biopharma Inc. Presents Clinical Data from VBP101	23-02-16	CI
PureTech founded entity Vor Bio first AML patient gets transplant	22-12-08	AN
Vor Bio Announces First AML Patient Successfully Transplanted with VOR Bio's Investigational Trem-Cel and Tolerated Mylotarg(Tm)	22-12-07	CI
Vor Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Vor Bio Announces Opening of its New In-House Clinical Manufacturing Facility in Cambridge, MA	22-09-28	CI
Vor Biopharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA	22-06-10	CI
Vor Biopharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
Vor Biopharma, Akron BioProducts Partner to Develop Nucleases	22-03-22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Vor Biopharma Inc.

Equities

VOR

US9290331084

Highlights

Filters